Get the SPI Wire

JAGUAR HEALTH, INC.

NASDAQ:JAGX
Annual Meeting

of Shareholders

MEETING DATE

09/04/2026
DEF 14A FILED
08/03/2026
PUBLISHED
08/03/2026 8:37 pm
TIME TO PUBLISH
08/05/2026
METHODOLOGY
approve
EXCHANGE NASDAQ:JAGX · CUSIP 47010C805 · CLASS voting common stock, par value $0.0001 per share (the “Common Stock”), and Series Q Perpetual Preferred Stock, par value of $0.0001 per share (the “Series Q Preferred Stock”) · CIK 0001585608

RECONCILED · MIXED

Reconciled against the company’s Form 8-K Item 5.07 filed 2026-06-15.

4
FOR
0
AGAINST
0
WITHHOLD
4
BALLOT ITEMS

ITEM-BY-ITEM RECOMMENDATIONS

1
Approving, for purposes of Nasdaq Listing Rule 5635(d), the issuance of shares of our Common Stock issuable upon exchange of shares of our Series Q Perpetual Preferred Stock, par value $0.0001 per share (the “Series Q Preferred Stock”) issued to certain accredited investors
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states approval is sought under Nasdaq Listing Rule 5635(d) for these share issuances.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
2
Approving, for purposes of Rule 5635(d), the repricing of certain warrants issued to investors to purchase an aggregate of 60,781 shares of our Common Stock with exercise prices ranging from $35.00 to $266.44 per share (the “Investor Warrants”), so that each of the Investor Warrants has a new exercise price equal to $1.00 per share, which Investor Warrants when exercised will also entitle such investors to receive up to 682,661 shares of Common Stock from the Series O Preferred Stock Dividend
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states approval would make the warrant amendments effective, including a $1.00 exercise price.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
3
Approving an amendment and restatement of the Company’s 2014 Stock Incentive Plan (the “2014 Plan”) to increase the number of shares of Common Stock authorized for issuance under the 2014 Plan to 14% of the issued and outstanding shares of Common Stock on a fully diluted basis as of September 30, 2026
compensation
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states the 2014 Plan could run out of available shares as soon as third quarter 2026.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.
4
Approving a proposal to approve one or more adjournments of the Special Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of the Special Meeting to approve Proposals 1, 2 and 3
other
Routine
For
Board FOR · Duopoly unknown — No divergence flagged

Filing states adjournment may be used to solicit additional proxies for Proposals 1, 2 and 3.

Divergence: 0 Review status: Approved. Publication ledger and 8-K reconciliation pending.

Ledger

8cf5148c7f2e0781fddbb352b56148f69d2a7ebeff7fba3864b1dfa831c3ed04

Search company, ticker, executive, director or issue

    The SPI Wire · Proxy Intelligence

    Get every ballot call, before the vote.

    FOR, AGAINST or WITHHOLD on each covered ballot item — published within 48 hours of the definitive proxy filing. Follow the companies you own, or take the full feed.




    Pick the companies you own — you’ll only hear from us on their ballots.

    The SPI Wire covers proxy ballots only — it has nothing to do with Signal Research investigations. Research and analysis for informational purposes; not legal, investment, or voting advice. Unsubscribe anytime.

    Submit Information








      Join Monitoring List




        Receive Research Updates